Pharmacogenomics Research Network (U01/U19)
The summary for the Pharmacogenomics Research Network (U01/U19) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Pharmacogenomics Research Network (U01/U19): Purpose. The purpose of this funding opportunity announcement issued by NIGMS, NHLBI, NCI, NIDA, NIMH, and NICHD is to allow new and renewal applications for research groups to compete to become part of the Pharmacogenomics Research Network (PGRN), and to create network resources that serve the entire PGRN. The PGRN is a consortium of interdisciplinary groups with a core mission to conduct research into understanding the genetic basis of variable drug responses, both therapeutic and adverse. The scientific objectives of the research network include definition of the pressing problems for safe and effective use of medications, establishment of truly cross-disciplinary research groups, application of the most appropriate genetic and genomic methods to important sample collections, discovery and replication studies that identify variation in critical genes and biological pathways, elucidation of the functional consequences of genetic variation for the drugs being studied, and understanding the clinical implications of genotyping to predict drug responses
Federal Grant Title: | Pharmacogenomics Research Network (U01/U19) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-GM-10-001 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.209 |
CFDA Descriptions: | Contraception and Infertility Research Loan Repayment Program |
Current Application Deadline: | Jun 02, 2009 |
Original Application Deadline: | Jun 02, 2009 |
Posted Date: | Jan 30, 2009 |
Creation Date: | Jan 30, 2009 |
Archive Date: | Jul 03, 2009 |
Total Program Funding: | $30,000,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs).
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Opportunity PAR-09-120
- • Opportunity PA-08-193
- • Opportunity PA-08-192
- • Behavioral and Social Research on Disasters and Health (R01)
- • Behavioral and Social Research on Disasters and Health (R03)
- • Opportunity PA-06-452
- More Grants from the National Institutes of Health
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...
- • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...